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NF-κBMany transcription factors are known to control transcription at several promoters, while others are only
active at a few places. However, due to their importance in controlling cellular functions, aberrant
transcription factor function and inappropriate gene regulation have been shown to play a causal role in a
large number of diseases and developmental disorders. Inﬂammatory bowel disease (IBD) is characterized by
a chronically inﬂamed mucosa caused by dysregulation of the intestinal immune homeostasis. The aetiology
of IBD is thought to be a combination of genetic and environmental factors, including luminal bacteria. The
Caudal-related homeobox transcription factor 2 (CDX2) is critical in early intestinal differentiation and has
been implicated as a master regulator of the intestinal homeostasis and permeability in adults. When
expressed, CDX2 modulates a diverse set of processes including cell proliferation, differentiation, cell
adhesion, migration, and tumorigenesis. In addition to these critical cellular processes, there is increasing
evidence for linking CDX2 to intestinal inﬂammation. The aim of the present paper was to review the current
knowledge of CDX2 in regulation of the intestinal homeostasis and further to reveal its potential role in
inﬂammation.disease; CDX2, Caudal-related
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The intestinal epithelium is the most vigorously self-renewing
tissue of adult mammals. The continuous renewal of intestinal
epithelium provides several unique challenges.
Thus rates of intestinal cell production must be precisely balanced
by cell loss or destruction; otherwise, the epithelial barrier function is
compromised. Cell proliferation and differentiation are tightly
controlled in the normal intestinal epithelium. Various genes and
transcription factors may take part in this process, in which some are
up-regulated and others are down-regulated. One of these well-
studied factors is the homeodomain protein CDX2. CDX2 is an
intestine-speciﬁc transcription factor known to act as a major protein
regulator, governing expression of numerous intestine-speciﬁc genes[1] and to modulate cellular processes such as cell differentiation,
proliferation, cell adhesion, migration, and tumorigenesis. Therefore,
bymodulating these processes and regulating genes, CDX2 is essential
in intestinal homeostasis and for the maintenance of an intestinal cell
phenotype. Thus, loss of accurate control of CDX2 expression has been
demonstrated to cause serious disruption of the mucosal architecture,
leading to intestinal diseases and developmental disorders. In
addition to these speciﬁc roles, increasing knowledge indicates that
CDX2 may be pivotal in intestinal inﬂammation. In fact, a linkage
between the key pathways involved in inﬂammation and regulators of
homeostasis is often seen [2], supporting the hypothesis that there is a
connection between inﬂammation and CDX2 expression.
In this review, we summarize the importance of CDX2 in gut
homeostasis and additionally discuss the relationship between
molecular pathways involved in intestinal inﬂammation and CDX2
expression.2. Review criteria
The search “Cdx2 cancer, Cdx2 ERK, Cdx2 homeostasis, Cdx2
inﬂammation, Cdx NF-κB, Cdx2 p38, inﬂammatory bowel disease, and
MAP kinase inﬂammation”was performed in the PubMed database up
to November 2010. English-language original papers, reviews, short
communications, and articles were evaluated. Subsequently, articles
were selected based on their scientiﬁc and clinical relevance.
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The homeobox gene, Caudal, was originally identiﬁed in Drosophila
[3], but subsequently other Caudal homologue transcription factors
have been identiﬁed in a wide array of organisms having pivotal roles
in intestinal epithelial development and maintenance [4–7]. Three
Caudalhomologue genes (CDX1, CDX2, and CDX4) have been identiﬁed
in mammals, which are expressed during embryonic development,
and they contribute to axial patterning [8–11]. In adult mammals, the
CDX1 and CDX2 homeoproteins have been found to be intestine-
speciﬁc transcription factors regulating homeostasis of the continu-
ously renewing intestinal epithelium. However, the role of CDX4 in
adults is yet unknown. During adulthood, the CDX1 and CDX2 genes
seem to be differently expressed in the intestinal epithelial cells and
along the crypt–villus axis [12]. The expression of CDX1 is restricted to
the proliferating cells of the crypt compartment [13], while CDX2 is
found in all epithelial cells located in the crypt–villus epithelium of the
small intestine and colon [6,14], but CDX2 is active in differentiating
enterocytes [15]. By transactivating the promoters of several intestine-
speciﬁc genes, both CDX1 and CDX2may be involved in the regulation
of proliferation and differentiation of intestinal epithelial cells [16–18].
In fact, CDX2 is directly involved in the activation of some of the genes
characteristic for enterocytic functions such as Sucrase-isomaltase,
Lactase-phlorizin hydrolase, Calbindin-D9K, and Hephaestin genes
[6,19–21].
In the mouse embryo, the ﬁrst stage of Cdx1 expression is from E
(embryonic day) 7.5 to 12, with early expression in the ectoderm and
mesoderm of the primitive streak and later in the developing neu-
roectoderm, somites, and developing limb buds [22]. Cdx2 expression
begins as early as E3.5 and is conﬁned to the trophectoderm and
persists in the extra-embryonic ectoderm. From E8.5, Cdx2 is
expressed in the posterior gut endoderm, neural tube, and tail bud
[23]. By E12.5, the expression of Cdx2 is restricted to the endoderm of
the gut [8,24]. The expression of both Cdx1 and Cdx2 increases
signiﬁcantly during the transformation of endoderm into a columnar
epithelium (E14–E17) [12].
To directly address the function of CDX1 and CDX2 proteins during
early development, transgenic models have been investigated. Mice
embryos with inactivated Cdx2 alleles (Cdx2−/−) leads to early lethality
due to an implantation failure [25], while Cdx1-null mice are viable and
show anterior homeotic transformation of the axial skeleton [26]. Cdx2
heterozygotes are viable and fertile; however, the colon and small
intestine shows Cdx2-deﬁcient lesionswith gastric-like epithelium [27].
This has further been supported by conditional homozygotes Cdx2
knockout mice created by Gao et al. [28]. These mice had an abnormal
colon, as the colonocytes differentiate into a gastric rather than into an
intestinal phenotype and thus exhibits loss of intestinal morphology.
Additionally, ectopic expression of Cdx2 in the stomach of transgenic
mice triggers intestinal-like heterodifferentiation of the gastric mucosa,
supporting the notion that Cdx2 is critical in both intestinal cell
differentiation and in maintaining the intestinal phenotype [29,30].
Taken together, these transgenic data demonstrate that CDX2 has
a crucial homeotic function during intestinal differentiation.
Owing to the essential role of CDX2 in intestinal development and
cell phenotype, the transcriptional gene regulation of CDX2 has been
the focus of numerous studies. In this context, Benahmed et al. [31]
used various transgenic genomic fragments of the mouse Cdx2 locus
and demonstrated that the fragments containing the ﬁrst −5 kb
upstream of the transcriptional start site is necessary in order to
activate Cdx2 expression during gastrulation but became inactive at
mid-gestation. However, the authors reported that genomic fragments
extending to−9 kb is required to maintain the expression of Cdx2 in
the midgut region of the endoderm into adulthood. They demonstrat-
ed a 250-bp segment around−8.5 kb that revealed interactions with
hepatic nuclear factor 4α (HNF4α), GATA-binding protein 6, T-cellfactor 4 (Tcf4), and β-catenin. In HeLa cells, these transcription factors
activated endogenous expression of Cdx2 synergistically in co-
transfection experiments with a Cdx2-luciferase construct. Further-
more, CDX2 has been found to be able to positively autoregulate its
own expression [1,32].
The transcriptional activity of the CDX2 protein is also regulated at
the post-translational level. CDX2 expression persists throughout life
in the intestinal epithelium and various phosphorylated forms coexist,
exerting different effects on cell behavior [33]. It has been established
that CDX2 is phosphorylated within the amino-terminal region by the
mitogen-activated protein kinases (MAPKs) and that this modulates
CDX2 transcriptional activity [15,34]. The phosphorylation of CDX2
has also been shown to inﬂuence the stability of the protein. Gross
et al. [33] demonstrated that cyclin-dependent kinase 2 (CDK2)
phosphorylates CDX2 at serine 281 and controls its degradation via
polyubiquitination.
In summary, CDX2 is regulated by a combination of transcription
factors of importance for intestinal differentiation and functional
properties of the intestinal epithelial cell.
4. CDX2 and colon cancer
Different lines of evidence suggest that CDX2 may suppress
colorectal tumorigenesis [25,35,36]. Indeed, the expression of CDX2
is often reduced in a subset of primary colon cancers [37–39], and cell
differentiation is poor in tumors that loose CDX2 [40]. Moreover,
heterozygous Cdx2+/− mice are viable and fertile; however, they
develop multiple polyp-like lesions of the colon [25], and Cdx2+/−
mice treated with a carcinogenic compound, azoxymethane, seems to
possess an increased risk for tumor development [36]. Some reports
have, however, questionedwhether CDX2has a tumor suppressor role,
as some studies did not show any reduction in the CDX2 expression
level in tumors, as compared with normal mucosa [41,42], and
additionally heterozygous Cdx2+/−mice seemed to be more resistant
to colonic cancers induced by chronic inﬂammation [43]. Therefore,
revealing the underlying mechanisms of a diminished CDX2 expres-
sion during tumorigenesis might clarify the pathogenesis of colon
cancers.
5. CDX2 regulates intestinal permeability
The intestinal epithelial barrier is established by a single cellular
layer, and it plays a critical role in the transport of nutrients. Injury of
the epithelial layer requires a complex interplay between prolifera-
tion and migration of cells to restore the intestinal morphology. Apart
from its importance in the development of the gut, CDX2 contributes
to the balance between differentiation, proliferation, and cell renewal
of the mature intestine. Even though the precise role of CDX2 on the
migratory process of cells has not yet been established, there are some
indications for its inﬂuence on cell migration. Rao et al. [44] showed
that overexpression of CDX2 in intestinal epithelial cells increased cell
migration in wound healing, while a more recent work of Gross et al.
[45] indicated that a decreasing CDX2 expression enhanced the mi-
gration of intestinal cells. Moreover, recently it has been demon-
strated that CDX2 regulates the transcriptional regulation of the
engulfment and cell motility 3 (ELMO3) gene [46], which is assumed to
function as an essential upstream regulator of the monomeric GTP-
binding protein, Rac, during cell migration [47].
Cell–cell interactions and the expression of adhesion molecules are
important regulators of intestinal proliferation, apoptosis, and migra-
tion. The intestinal epithelial cells are held together by intercellular
junctions that include both adherence and tight junctions. The seal that
regulates paracellular permeability is established by the tight junction,
which is composed of transmembrane adhesions molecules, e.g.,
claudins and occludin, and cytosolic proteins [48]. An intact intestinal
epithelial tight junction barrier is crucial in providing a barrier function
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immune system homeostasis. Accordingly, three adhesion genes, LI-
cadherin, E-cadherin, and Claudin-2 (CLDN2), have been reported as
CDX2-targets [49–51]. These proteins are critical in the establishment
and maintenance of cell adhesion and the intestinal cell polarity. In
addition to tight junction proteins, the continuity and stability of the
mucus layer is of importance for the intestinal homeostasis.
Mucins produced by goblet cells comprise the main structural
components of the mucus layer and forms the primary barrier against
pathogenic infections [52]. The predominant secretory mucin pro-
duced by goblet cells is mucin 2 (MUC2) [53–55], and interestingly,
MUC2 has also been reported to be a CDX2-target gene [56,57].
Studies on human tissues have shown that a dysfunction of the
intestinal innate immunity and an altered expression and structural
changes of the intestinal tight junction proteins and mucins are
closely associated with the development of cancer and inﬂammatory
bowel disease (IBD) [58–61]. Given the strategic position of CDX2 at
the crossroads of regulating numerous intestinal genes on the one
hand and preserving intestinal homeostasis and permeability on the
other hand, it is obvious that a proper regulation of CDX2 expression
and activity is of importance for maintaining a normal intestinal
epithelia barrier.
6. Linking CDX2 to intestinal inﬂammation
IBD is characterized as a chronic idiopathic inﬂammation of the
intestine and is an umbrella term for different diseases of which
ulcerative colitis (UC) and Crohn's disease (CD) are the two most
common entities. The inﬂammation in UC is localized exclusively to
the colon, whereas CD is characterized by deep (transmural)
segmental inﬂammatory lesions, which might occur anywhere in
the gastrointestinal tract, the prevailing site is, however, the terminal
ileum. The most common symptoms seen in UC are bloody stools and
diarrhea, while in CD, it is diarrhea, weight loss, abdominal cramps,
and pain.
The aetiology of IBD is thought to be a combination of genetic and
environmental factors. Thus, chronic intestinal inﬂammation might
occur among genetic predisposed individuals affecting the mucosal
immune system [62–64], combined with luminal bacteria or infec-
tions (e.g., inﬂammatory signals) [65,66]. Beside pro- and anti-
inﬂammatorymediators and themolecular pathways regulating these
factors, studies have investigated the role of CDX2 in the inﬂamma-
tory process. One study has shown that CDX2 expression is repressed
by the pro-inﬂammatory cytokine tumor necrosis factor α (TNF-α)
[67] (Fig. 1), which are found in increased concentrations in the
inﬂamed intestines of active UC and CD [68,69]. Surprisingly, Sipos et
al. [70] have recently reported a low expression level of CDX2 in
inﬂamed UC, but with no signiﬁcant correlation to inﬂammation. As
previously described, CDX2 is a positive regulator of CLDN2 [51] and
MUC2 genes [56,57] with an essential role of the intestinal epithelial
barrier function. Interestingly, both CLDN2 [61,71] and MUC2 [72,73]
expressions are affected by the inﬂammatory mediators interleukin
(IL)-13 and TNF-α. Additionally, secretion of MUC2 is also reduced in
the active stage of UC resulting in a thinner layer of mucus as
compared to healthy individuals [74]. Furthermore, Kaneko et al. [75]
have reported that CDX2 and MUC2 expressions are decreased in the
ulcer-associated cell lineage, which occurs at sites of chronic
ulceration in CD, with a histological differentiation resembling gastric
mucosa.
CDX2 has additionally been reported to positively regulate the H+-
coupled peptide transporter 1 (PEPT1) [76]. PEPT1 is an integral
membrane-spanning protein transporting di- and tripeptides and is
expressed in the inﬂamed colon of IBD patients [77]. Reducing CDX2
could affect the regulation of PEPT1 and the intake of bacterial
peptides responsible for the production of immune molecules,
thereby increasing the risk for infections.The link between CDX2 and intestinal inﬂammation has also been
investigated in other species than humans. In Drosophila, inhibition of
Caudal resulted in overexpression of antimicrobial peptide genes,
which led to an increased bacterial growth with elevated apoptosis
[78]. Moreover, Calon et al. [43] have shown a linkage of CDX2 to
inﬂammation with experimental colitis models and demonstrated
that dextran sodium sulphate (DSS) in the drinking water of Cdx2+/−
mice led to an increased intestinal permeability. These animals
showed a high susceptibility to development of DSS-induced acute
colitis [43], suggesting that Cdx2 is involved in protection against
DSS-induced colitis.
Taken togetherwith the observations that (1) CDX2 is a downstream
target of inﬂammatory cytokines, (2) expression of CDX2 is reduced in
inﬂamed tissues, (3) heterozygotes Cdx2 mice are sensitive to DSS-
induced acute colitis, and (4) CDX2 is essential in the regulatory
mechanism of genes involved in mucosal permeability, these facts
indicate that CDX2 is involved in intestinal inﬂammation. Therefore, an
altered CDX2 expression and activity may change several functions and
properties of the epithelium to trigger infections and inﬂammation.
6.1. Cytokine induced NF-κB pathway regulates CDX2 expression
Inﬂammatory cytokines are key mediators in the pathogenesis of
IBD, and a study has reported a TNF-α-mediated regulation of the
CDX2 gene expression during inﬂammation [67]. This study indicates
that the TNF-α regulated CDX2 expression in vitro is actually
mediated by nuclear factor (NF)-κB activation.
The NF-κB family of transcription factors consists of ﬁve mamma-
lian members (p50, p52, p65, cRel, and RelB) [79,80], which can form
homodimers or heterodimers. NF-κB is a key regulator in IBD [81,82].
The expression and activation of NF-κB are strongly enhanced in the
inﬂamed gut of patients with IBD [83,84] and promote the expression
of various pro-inﬂammatory cytokines including IL-1, IL-2, IL-6, IL-8,
IL-12, and TNF-α [85,86] (Fig. 1). In addition to an enhanced ex-
pression and activity of NF-κB in IBD patients, a constitutive activation
of the NF-κB pathway is involved in some malignancies including
leukemia, lymphoma, colon cancer, and ovarian cancer [87,88]. NF-κB
additionally promotes the expression of a wide variety of genes that
are important for the activation of immune responses, including genes
encoding chemokines, adhesion molecules, enzymes, and genes that
facilitate proliferation, tumor promotion, andmetastatic development
[89]. Furthermore, NF-κB is important for regulation of genes coding
for regulators of apoptosis, such as cIAP, BCL-X, FLIP, and XIAP [90,91].
Interestingly, Kim et al. [67] have identiﬁed two putative NF-κB
binding sites in the CDX2 promoter, suggesting a direct transcriptional
regulation controlled by the balance between p50 and p65 subunits of
NF-κB. They have shown that the CDX2 promoter is able to bind both
p50/p50 and p65/p50 dimers, where the activity of the CDX2
promoter is increased by the p50/p50 homodimer, and the binding
of p65/p50 heterodimer decreased CDX2 expression [67] (Fig. 1).
Furthermore, they demonstrated that the DNA-binding activities of
the p50/p50 or p65/p50 dimers are mediated by the phosphatase and
tensin homolog (PTEN) and the phosphatidylinositol 3-kinase (PI3K)
pathways [67] (Fig. 1). PTEN is a tumor suppressor protein that
antagonizes the activity of PI3K by dephosphorylating the D3
phosphate group of a lipid second messenger, phopshatidylinositol
3,4,5-triphosphate, that is produced by PI3K [92]. Additionally, studies
have reported that CDX2 can reduce NF-κB regulated gene expres-
sion [93–95]. In these studies, CDX2 interacts with the p65/p50
heterodimer of NF-κB and prevent it from forming transcriptional
active DNA complexes and thereby reduces cyclooxygenase (COX)-2
and cyclin D1 expressions, respectively.
COX-2 is an inducible pro-inﬂammatory enzyme [96] playing a key
role in inﬂammatory cascades and cancer where arachidonic acid is
involved [97,98], and it is positively regulated by NF-κB activation
[99]. Taken together, the interaction between NF-κB and CDX2 could
Fig. 1. Regulation of CDX2 expression by inﬂammatory mediators. Extracellular stimuli from cytokines or inﬂammatory mediators activate either the MAPK signaling or the NF-κB
signaling pathway to induce CDX2 expression. The mammalian MAPK family includes ERK, p38, and JNK. Activated MAPKs phosphorylate various substrate proteins including
transcription factors resulting in the regulation of various cellular activities including cell survival, inﬂammation, and proliferation. Both p38 and ERK can phosphorylate CDX2, but
p38 activates whereas ERK inactivates the transcriptional activity of CDX2. NF-κB has a pivotal role in inﬂammation. PTEN activity via NF-κB upregulates CDX2 expression and is
antagonized by PI3K signaling. When expressed, CDX2 modulates a diverse set of processes including cell differentiation, cell adhesion, and tumorigenesis.
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DNA-binding activity of p50/p50 and p65/p50 in gene expression
(Fig. 1). In fact, as previously described, inhibition of Caudal in
Drosophila resulted in overexpression of antimicrobial peptide genes
leading to an increased bacterial growth with elevated apoptosis [78].
Furthermore, it has been reported that the expression of antimicrobial
peptides is controlled by the balance between Caudal and NF-κB. Thus,
it is likely that stimuli from pro-inﬂammatory cytokines, e.g., TNF-α,
activate the NF-κB pathway and through PTEN or PI3K activity, NF-κB
might regulate the CDX2 expression in IBD (Fig. 1).
6.2. Stimuli-dependent MAPK signaling regulates CDX2 activity
As illustrated in Fig. 1, in addition to the above described NF-κB
pathway, extracellular stimuli from, e.g., cytokines or inﬂammatory
mediators also activate the MAPK pathway. The MAPK super-family is
composed of threemajor sets of kinases inmammals: the extracellular
signal-regulated kinases (ERKs), the c-Jun N-terminal kinase (JNK),
and p38 MAPKs [100,101]. Activation of speciﬁc MAPKs involves
phosphorylation and activation of upstream kinases. MAPKs are
members of intracellular kinases that are involved in a wide range of
cellular events associated with the inﬂammatory response, as well as
cell proliferation and survival [101,102]. Consistent with their critical
roles in various key cellular activities, the MAPK signaling pathways
have been implicated in the pathogenesis of several human diseases
[103–105]. ERK1/2 are the most studied ERK MAPKs and works
through activation of the activator protein (AP)-1 family of transcrip-
tion factors (composed of members of Jun, Fos, Maf, and ATF
subfamily) [106] and the phosphorylation of the transcription factor,cAMP response element binding protein (CREB) [107]. Through
phosphorylation and activation of AP-1 and CREB, ERK1/2 mediates
its transcriptional function. ERK1/2 has been found to induce
expression of the pro-inﬂammatory cytokine IL-1 in IBD [108] and is
overexpressed in inﬂamed tissueswith increasedphosphorylation and
elevated activation [109].
In addition to ERK1/2, increased activation of p38 and JNK MAPKs
has also been found in IBD patients [109,110]. p38 and JNK MAPKs
have many downstream targets in common, including IL-1, IL-6, IL-8,
TNF-α, and members of the AP-1 family of transcription factors
[111,112] (Fig. 1). However, p38 MAPK also activates transcription
factors like CREB and NF-κB [99]. Interestingly, ERK1/2 has been
shown to phosphorylate CDX2 at Serine 60 to reduce its transcrip-
tional activity [15], and recently Krueger et al. [113] have conﬁrmed
these ﬁndings in cancer cells, while phosphorylation of CDX2 by p38
MAPK accompanies cell differentiation and enhances its transcrip-
tional activity [34]. However, the p38 MAPK mediated phosphoryla-
tion of CDX2 is dependent on type of stimulus and signaling. In fact,
the previously described regulation of COX-2 by NF-κB activation is
p38 MAPK-dependent, as the p65 subunit of NF-κB is repressed when
p38 activity was inhibited [99].
The last subfamily of the above-described MAPKs is the JNK MAPK.
JNKwas originally identiﬁed by its ability to speciﬁcally phosphorylate
the transcription factor c-Jun on its N-terminal transactivation
domain. There are yet no evidence for a direct regulatory link between
JNK and CDX2 activity. However, the JNK pathway, together with NF-
κB, has been reported to play important roles in numerous physiolog-
ical processes [114]. Studies have shown a negative regulation
between JNK and NF-κB signaling, which is involved in the regulation
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through NF-κB activation induces MUC2 transcription, whereas JNK
activation inhibits this induction in human colonic epithelial cells.
Taken together, it is likely that CDX2 as a positive regulator of MUC2
may counter-balance the suppressive effects of TNF-α/JNK mediated
down-regulation of MUC2 expression to prevent inﬂammation.
Thus, there are indications that CDX2 may be involved in the
inﬂammatory process; therefore, it is important to dissect themolecular
mechanisms underlying the interplay between inﬂammatory pathways
in greater detail, in particularwith respect to the regulation of CDX2 and
its relation to inﬂammation.
7. Conclusions
The intestine-speciﬁc homeobox transcription factor CDX2 is of
importance for the intestinal differentiation and homeostasis. There is
clear evidence for implicating the CDX2 factor in modulating a diverse
set of cellular processes, including cell proliferation, differentiation,
cell adhesion, migration, and tumorigenesis. However, what is less
clear is the role of this factor in relation to gut inﬂammation.
There is increasing evidence that CDX2 is a downstream target of
key pro-inﬂammatory mediators and signaling pathways involved in
the inﬂammatory cascade. Thus, inﬂammatory mediators have been
mechanistically linked with the regulation of CDX2 expression, and a
decreased CDX2 expression in inﬂamed cells in UC has been reported.
Furthermore, CDX2 has an impact on mucosal permeability and
down-regulation of pro-inﬂammatory genes.
Therefore, an altered CDX2 expression can disrupt the mucosa in
protecting the host against its luminal components in the intestine,
which might result in an increased expression of inﬂammatory
mediators, potentially leading to episodes of colonic inﬂammation, as
observed in IBD.
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